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Abstract 
Clinical manifestations of Alzheimer’s disease (AD) are associated with a breakdown in large-scale 
communication, such that AD may be considered as a “disconnection syndrome”. An established 
method to test effective connectivity is the combination of transcranial magnetic stimulation with 
electroencephalography (TMS–EEG), because the TMS-induced cortical response propagates to 
distant anatomically connected regions. To investigate whether prefrontal connectivity alterations 
may predict disease severity, we explored the relationship of dorsolateral prefrontal cortex 
connectivity (derived from TMS–EEG) with cognitive decline (measured with Mini Mental State 
Examination and a face–name association memory task) in 26 AD patients. The amplitude of 
TMS–EEG evoked component P30, which was found to be generated in the right superior parietal 
cortex, predicted MMSE and face–name memory scores: higher P30 amplitudes predicted poorer 
cognitive and memory performances. The present results indicate that advancing disease severity 
might be associated with effective connectivity increase involving long-distance frontoparietal 
connections, which might represent a maladaptive pathogenic mechanism reflecting a damaged 
excitatory–inhibitory balance between anterior and posterior regions.  
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1. Introduction 
Alzheimer’s disease (AD) is a common progressive neurodegenerative disorder that disturbs several 
cognitive functions with the core difficulties involving episodic memory (Dubois et al., 2007). 
Converging neuroimaging and electrophysiological results have demonstrated that the clinical 
manifestations of AD are not associated only with regional gray matter dysfunction but also with a 
breakdown in the communication between brain regions due to compromised large-scale 
connections, leading scientists to consider AD as a “disconnection syndrome” (Delbeuck et al., 
2003). Magnetic resonance imaging (MRI), positron emission tomography (PET) and 
electroencephalography (EEG) have primarily indicated alterations in frontoparietal connectivity, 
together with weakened interhemispheric interactions (Berendse et al., 2000; Grady et al., 2001; 
Horwitz et al., 1987; Rose et al., 2000).   
Loss of connectivity is not an “all at once” phenomenon in a brain affected by AD (Delbeuck et al., 
2003) but rather connectivity is altered at several stages that mirror changes in AD pathology. In the 
prodromal and early stages of AD, resting-state functional MRI (fMRI) studies have consistently 
found a weakened connectivity in posterior brain regions (Agosta et al., 2012; Brier et al., 2012; 
Greicius et al., 2004; Sorg et al., 2007; Wang et al., 2007, 2006; Zhang et al., 2010; Zhou et al., 
2010) coupled with an increased anterior connectivity, either within the prefrontal regions or 
between prefrontal areas and other brain regions (Agosta et al., 2012; Filippi et al., 2013; Supekar et 
al., 2008; Wang et al., 2007, 2006; Zamboni et al., 2013; Zhou et al., 2010). Looking at the full 
spectrum of AD pathology, abnormalities first affect the medial temporal lobe, the posterior 
cingulate cortex and the precuneus (Braak and Braak, 1991; Buckner, 2005; Buckner et al., 2008; 
Greicius et al., 2004; Sorg et al., 2007; Sperling et al., 2010; Zhou et al., 2010), then spread to 
posterior lateral cortical areas, and finally to frontal regions in overt AD (Braak and Braak, 1991; 
Zhang et al., 2010).  
Therefore, prefrontal cortex represents a crucial target area to investigate how connectivity is 
altered at different stages of AD severity once clinical signs of are overt, as these regions are 
affected in a late stage of the disease (Braak and Braak, 1991).  
However, only a few works have investigated how connectivity alterations further change over time 
once AD symptoms are manifested. Zhang and coworkers (Zhang et al., 2010) investigated resting-
state functional connectivity alterations in patients with mild, moderate and severe AD, revealing 
that connectivity in the posterior cingulate cortex decreases but prefrontal connectivity increases 
with the progression of the disease. A longitudinal resting-state fMRI study by Damoiseaux et al.  
(2012) showed that connectivity decreases in posterior and increased in anterior areas at the very 
mild stage of the disease. However, when considering long-term changes, connectivity was found to 
decrease in all regions. Moreover, the functional implication of prefrontal connectivity alterations is 
still unclear. Although several authors have suggested that the enhanced prefrontal connectivity 
reflects a compensatory effect (Agosta et al., 2012; Gour et al., 2014; Supekar et al., 2008; Wang et 
al., 2007, 2006; Zamboni et al., 2013), the basis of such a phenomenon has not been elucidated 
(Pievani et al., 2014, 2011). According to the “compensatory hypothesis”, AD patients recruit 
additional frontal regions to compensate for the impaired posterior connectivity and for the resulting 
loss of cognitive functioning. An alternative explanation put forward by Pievani and colleagues 
(Pievani et al., 2014, 2011) is that, on the contrary, connectivity enhancement might represent a 
pathogenic mechanism due to damaged excitatory–inhibitory balance between anterior and 
posterior brain regions.   
The prefrontal cortex, specifically the dorsolateral prefrontal cortex (DLPFC), is critically involved 
in episodic memory (Eichenbaum, 2017) and is the target of most of the non-invasive brain 
stimulation interventions aimed at improving this function. Crucially, episodic memory impairment 
is the core hallmark of AD cognitive profile, with trouble putting names to faces representing a 
distinct clinical manifestation and one of the most disabling symptoms. Accordingly, face–name 
associative memory tasks, which provide highly sensitive indices of episodic and semantic memory 
performance, are exploited to capture episodic memory difficulties in AD and can contribute to 
characterize different stages of disease severity (Parra et al., 2010; Werheid and Clare, 2007). 
Neuroimaging studies have revealed that in face–name associations, memory requires both highly 
specialized cortical areas in the occipitotemporal cortex and other brain regions associated with 
higher cognitive functions, including the DLPFC (D’Esposito et al., 1995; Sperling et al., 2001; 
Wagner et al., 1998). 
Brain connectivity, and more specifically effective connectivity, can be tested by means of the 
combination of transcranial magnetic stimulation (TMS) with EEG (TMS–EEG). This method 
allows one to measure cortical excitability and effective connectivity in brain networks by 
measuring cortical signals evoked by TMS in the target area and their propagation to connected 
regions (i.e., TMS-evoked potentials, TEPs) (Bortoletto et al., 2015). TEPs offer an opportunity 
to probe the causal influence that one region exerts on another because the activation induced 
by the TMS pulse in the stimulated area spreads to directly or indirectly connected areas. 
This spread is measured through EEG as amplitude and latency of TEPs generated in remote 
regions (Bortoletto et al., 2015; Ilmoniemi et al., 1997; Massimini et al., 2005; Morishima et al., 
2009). Compared to fMRI-based effective connectivity, TEPs-based effective connectivity has 
high temporal resolution and low spatial resolution (as determined by EEG properties); its 
estimation does not require strong a priori assumptions and complex causal models, such as 
Granger causality.  TMS–EEG is an attractive technique because it is non-invasive, painless and 
easily accessible (Hohenfeld et al., 2018). Furthermore, being performed in a resting-state 
condition, TMS–EEG seems particularly suitable for AD patients, even at the severe stages of the 
disease, as it is less demanding for the patient and relatively independent from his/her active 
collaboration. A few studies have already demonstrated the feasibility of TMS–EEG in AD 
(Casarotto et al., 2011; Ferreri et al., 2016; Julkunen et al., 2011, 2008) by showing alterations in 
excitability and connectivity. However, only a very small number of patients have been studied or 
the target has been the motor cortex, with only marginal relevance in AD clinical manifestations.  
The aim of the present study was to determine how prefrontal connectivity alterations are related to 
AD clinical symptoms and may predict disease severity in overt AD through a cross-sectional 
design. We explored the relationship between the excitability and effective connectivity of the 
DLPFC (as derived from TMS–EEG) and cognitive decline (as measured with Mini Mental State 
Examination and a face–name association memory task) in a sample of overt AD patients. 
 
2. Material and methods 
2.1 Participants 
34 right-handed mild to moderate AD patients (age = 77.6, sd = 4.8, range = 64–84; Mini Mental 
State Examination (MMSE) score = 20.8, sd = 2.3, range = 17–26) were recruited and underwent a 
clinical and neuropsychological assessment and a TMS–EEG session. Diagnosis of probable AD 
was done by expert neurologists or geriatricians addressing medical history, clinical 
examination, neuropsychological testing and laboratory results such as computed 
tomography, MRI or PET. Inclusion criteria for AD patients were a diagnosis of probable AD 
according to the criteria of the NINCDS-ADRDA work group (McKhann et al., 1984), MMSE 
score (Folstein et al., 1975) greater than or equal to 16 and a Clinical Dementia Rating scale score 
(CDR) from 0.5 to 2. At the time of recruitment all patients were being treated with 
cholinesterase inhibitors (donepezil or rivastigmine) or memantine (1 mild and 2 moderate 
patients) and were on a stable dose for at least 3 months prior to the beginning of the study. 
Exclusion criteria were the presence of medical, neurological or psychiatric disorders that might 
interfere with the study or the presence of any contraindication for TMS (Rossi et al., 2009). All 
participants gave their written informed consent prior to the experiment. All the procedures 
conformed to the Declaration of Helsinki for research involving human subjects and were approved 
by the ethics committee of the IRCCS Centro San Giovanni di Dio Fatebenefratelli of Brescia 
(Italy). Data from 8 participants were excluded from the final sample due to technical problems 
during TMS–EEG recording. The final sample thus consisted of 26 participants. A subset of 20 
patients performed also a face–name association memory task (FNAT). Demographic data from 
the final sample are reported in Table 1.  
 
2.2 Clinical and neuropsychological assessment 
The clinical and neuropsychological assessment, administered by trained neuropsychologists, tested 
general cognitive abilities (MMSE), memory (Rey Auditory Verbal Learning test; recall of Rey–
Osterrieth Complex figure; Story Recall from Rivermead Behavioral Memory test), attentional and 
executive functions (Trail Making test, part A and B), language (Picture naming task; Battery for 
Analysis of Aphasic Deficits), and praxis (Rey–Osterrieth Complex figure). All the tests were 
administered and scored according to standard procedures (Lezak et al., 2012). Additionally, 
functional abilities were evaluated using basic and instrumental activity of daily living (BADL and 
IADL) scales (Katz, 1983; Lawton and Brody, 1969). The results of the assessments are reported in 
Table 1.   
 
---Please insert Table 1 about here--- 
 
2.3 Face–Name Association Memory Task  
The FNAT is an experimental computerized procedure for assessing episodic associative memory 
(Cotelli et al., 2014). FNAT included two phases: encoding and recognition. The stimuli were 
displayed on a 15-inch screen 60 cm in front of the patient with the Presentation software (Version 
14.9, www.neurobs.com). During the encoding phase, 60 unfamiliar faces paired with a set of 60 
unfamiliar first names (30 males, 30 females) were randomly presented. Patients were required to 
indicate whether the faces belonged to a man or a woman and then were required to encode the 
face–name associations. In the recognition phase, administered 10 minutes later, previously seen 
faces were again randomly presented together with four proper names (the correct, one novel, and 
two previously presented names). Patients were asked to indicate the correct name for each 
displayed face. For a detailed description of the task, see Cotelli et al. (Cotelli et al., 2014). FNAT 
scores are reported in Table 1. 
 
2.4 TMS protocol 
TMS was delivered with the Magstim Super Rapid (biphasic) stimulator through a standard 70-mm 
figure-of-eight coil. 200 TMS pulses were delivered over the left DLPFC at random intervals of 2–4 
seconds and with stimulus intensity of 110% of the resting motor threshold (rMT). To define rMT, 
the coil was placed tangentially on the scalp over the left primary motor cortex with the handle 
pointing backward at about 45° angle from the mid-sagittal axis of the participant’s head. rMT was 
measured as the lowest stimulus intensity required to elicit a motor evoked potential (MEP) of at 
least 50 µV in the relaxed right first dorsal interosseous (FDI) for 5 out of 10 consecutive trials 
(Rossini et al., 2015, 1994) . The mean rMT was 54.7 percent of the maximal stimulator output 
(%MSO) (sd = 8.0). To stimulate the left DLPFC, the coil was positioned tangentially over the 
scalp at about 45° angle away from the midline, resulting in a posterior–anterior current flow, and 
targeting the F3 electrode location (according to the International 10–20 System). The coil was held 
in place by an expert experimenter and monitored throughout the procedure. TMS pulses were 
delivered during a resting-state condition, with participants comfortably sitting and looking ahead 
toward a fixation point.  
 
2.5 EEG recording 
TMS-compatible EEG equipment (BrainAmp, Brain Products GmbH, Munich, Germany) recorded 
scalp potentials from 19 (Fp1, Fp2, F7, F3, Fz, F4, F8, T7, C3, Cz, C4, T8, P7, P3, Pz, P4, P8, O1, 
O2) TMS-compatible sintered Ag/AgCl electrodes (EasyCap, Brain Products). The signal was 
referenced online with respect to the nose and the ground electrode was at AFz. Horizontal and 
vertical eye movements were detected with electrodes placed at the left and right canthi and above 
and below the right eye, respectively. The impedance between the skin and each electrode was kept 
below 5 kΩ. A continuous recording mode without the use of any sample-and-hold circuit was 
adopted. The recorded signal was band-pass-filtered at 0.01–1000 Hz and digitized at a sampling 
rate of 5000 Hz.  
 
2.6 TMS–EEG analysis 
The EEG signals were processed and analyzed offline using EEGLAB (Delorme and Makeig, 2004) 
and custom scripts on MATLAB (R2016a, The MathWorks, Inc., Natick, Massachusetts). 
Continuous data were interpolated in the time range from –2 to 10 ms with respect to the TMS pulse 
and then filtered with a 0.1-Hz high-pass filter. Epochs were created around the TMS pulse, starting 
from 200 ms before it and ending 500 ms post-stimulus. Signal components corresponding to ocular 
artifacts (blinks and saccades) were identified and discarded by performing Independent 
Component Analysis (ICA) with the Infomax ICA algorithm. After ICA, the remaining 
measurement noise was removed with the SOUND algorithm (Mutanen et al., 2018), which is a 
Wiener-filtering-based technique designed for noise removal in EEG and MEG data. For the 
purpose of SOUND, the same spherical three-layer model and the same regularization parameter (
λ = 0.01) as applied in the original work (Mutanen et al., 2018) were used to clean the data. 
Because TMS–EEG data are likely to contain non-stationary disturbances, the collected data were 
cleaned with SOUND in 1-ms-long non-overlapping windows. For estimating the noise covariance 
matrix at each time window, the 5 samples per trial per each 1-ms window were used. In five 
patients, data were contaminated by TMS-evoked muscle artifacts; then, a method combining 
signal-space projection and source-informed reconstruction (SSP-SIR) (Mutanen et al., 2016) was 
applied to project out artifacts during the first 50 ms after the TMS pulse. One muscle-artifact 
component was removed from each dataset. The muscle-artifact components were identified based 
on each component’s time–frequency behavior and the corresponding signal power as explained in 
(Mutanen et al., 2016). Following SSP-SIR, data were filtered with a 70-Hz low-pass filter, visually 
inspected to discard epochs containing residual artifacts, re-referenced to the average of the 
mastoids and then baseline-corrected using the time interval from –100 to –2 ms.  
TEP amplitudes were determined by taking the maximal peak from the electrode exhibiting the 
highest amplitude, in the following time windows: 15–25 ms (positive peak over F3), 25–35 ms 
(positive peak over Cz), 45–55 ms (positive peak over Cz), and 60–80 ms (positive peak over P4). 
Later components were not analyzed because components at latencies of 100–200 ms may be 
related to an auditory evoked response associated with the sound of the TMS coil discharge 
(Nikouline et al., 1999), and the sensory response to the TMS upon the scalp tissue (Conde et al., 
2019). 
To characterize how the elicited brain activity spread from the stimulated spot to other areas, we 
localized each TEP component with sLORETA (sLORETA, Pascual-Marqui, 2002), a distributed-
source-imaging method. Briefly, sLORETA calculates the standardized neuronal current 
source density distribution consistent with the scalp topography in the cortical gray matter 
and the hippocampus of the template of the Montreal Neurological Institute 152 (MNI152) 
(Fuchs et al., 2002), which comprises 6239 gray-matter voxels at 5-mm spatial resolution. 
sLORETA estimates the underlying sources under the assumption that the neighboring voxels 
should have a maximally similar electrical activity; the result is a blurred, widespread 
solution in which the voxel with maximum current density is identified as the center of the 
source of the signal. Importantly, a previous systematic comparison study has shown that 
sLORETA can provide reasonably reliable source-current estimates when the traditional 10–20 
system is used (Song et al., 2015). 
 
2.7 Statistical analysis 
To investigate how TMS–EEG can predict disease severity, a linear regression was carried out for 
each TEP component, its amplitude value being the independent variable and the MMSE score the 
dependent variable. To detect the presence of outliers, Grubbs’s test was performed and if 
significant (α < 0.05), outlier values were removed. Outlier calculation identified only a significant 
value among P70 amplitude values (12.6 µV, p<0.05). In order to quantify the diagnostic ability of 
TEP components to discriminate between different stages of disease severity (mild vs moderate 
AD), receiver operating characteristic (ROC) curves were computed for the TEP components that 
showed a significant regression equation. The area under the curve index (AUC; 0.5<AUC>1, with 
1 indicating perfect accuracy) was provided as a measure of diagnostic performance, whereas 
sensitivity and specificity indices were provided to better evaluate the reliability of TEP 
components as biomarkers for distinguishing between mild and moderate AD. To do so, patients 
were classified in accordance with the National Health and Care Excellence guidance (2011) as 
mild AD if their MMSE score was greater or equal to 21 (N=13; MMSE score = 22.8 ± 2.0; age 
= 75.9 ± 5.6), and as moderate AD if their MMSE score was equal or less than 20 (N=13; 
MMSE score = 18.9 ± 1.0; age = 77.2 ± 4.0). In support of the adopted cut-off, MMSE score 
has been found to discriminate well between all CDR stages with scores of 21–25 and 11–20 
corresponding to mild and moderate dementia severity respectively (Perneczky et al., 2006).  
To compare mild and moderate AD patients in demographic, clinical and neuropsychological 
data, appropriate statistical tests, i.e. t-test for continuous variables and Chi-square for 
dichotomous variables, have been performed and are reported in Table 1.  
Moreover, to study the relationship between each TEP component and episodic memory 
dysfunction, a linear regression was calculated to predict FNAT performance (dependent variable) 
from TEP amplitudes (independent variable). Statistical analyses were conducted with IBM SPSS 
Statistics, Version 20.0 (IBM Corp., Armonk, NY).  
 
3. Results 
TMS to the left DLPFC elicited a complex pattern of activity both at the site of stimulation and at 
other areas. The grand-average waveform (Figure 1A) shows six main components on which 
sLORETA source localization was performed. The propagation of the evoked activity was traced by 
means of the scalp distribution of the EEG signals (Figure 1B) and their cortical source 
reconstructions (Figure 1C). The first detected component, peaking approximately at 20 ms (P20, 
localized in left anterior cingulate), was followed by the activation of the contralateral right superior 
parietal lobule at 30 ms (P30). The propagation of the signal induced a third component at 50 ms 
(P50, left superior frontal gyrus), followed by another positive peak at 70 ms (P70, left inferior 
frontal gyrus). The spatiotemporal evolution of the signal is shown in Figures 1B–1C.  
 
---Please insert Figure 1 about here--- 
 
Importantly, the P30 amplitude was predictive of the MMSE score in AD patients as revealed by 
the significant linear regression (F(1,21) = 5.19, p = 0.03, R2 = 0.20) (Figure 2A). No other significant 
regression relationship was found. ROC analysis (Figure 2B) revealed a good predictive 
performance of P30 amplitude in discriminating between mild and moderate AD patients (AUC = 
0.78). Considering a P30 amplitude value of 3.13 µV as a cut-off score, specificity and sensitivity 
indexes were 0.63 and 0.92, respectively.   
 
---Please insert Figure 2 about here--- 
 
As shown in Figure 3, a significant regression equation was found also when analyzing the 
relationship between P30 amplitude and FNAT (F(1,16) = 5.40, p = 0.03, R2 = 0.25). For the other 
TEP components, no significant relationship with FNAT were found.  
 
---Please insert Figure 3 about here--- 
  
4. Discussion 
The aim of the current study was to investigate how prefrontal TMS-evoked activity is associated 
with disease severity in a sample of mild and moderate AD patients. We found that the amplitude 
of P30, an early positive EEG response localized by sLORETA algorithm to the right superior 
parietal lobule, is augmented with more severe cognitive deterioration (lower MMSE score) and 
that this increase predicts disease severity. Additionally, P30 predicted performance in FNAT: a 
greater amplitude was associated with poorer memory performance.  
Despite being elicited by left DLPFC stimulation, P30 did not represent a direct local response of 
the prefrontal cortex. Source localization results suggested that P30 is generated by the activation of 
the right superior parietal cortex, possibly due to direct corticocortical signal transmission from the 
stimulated area. Indeed, the TEP represents the activation of the stimulated area followed by a 
spatiotemporal propagating pattern of activation (i.e., from the targeted region to other cortical areas 
that are the later sources of the response) via intra- and interhemispheric anatomical connections 
(Bortoletto et al., 2015; Ilmoniemi et al., 1997). Moreover, there is clear evidence of strong 
connections between prefrontal and parietal areas (Makris et al., 2005). Though TEPs do not 
demonstrate whether the effect of DLPFC stimulation on posterior parietal cortex is through direct 
connections or is mediated by another brain region, they do indicate a causal relation between the 
stimulation of prefrontal cortex and its effects over other activated areas. Therefore, P30 represents 
a measure of effective connectivity of long-distance interhemispheric cortical connections between 
the left DLPFC and the right superior parietal cortex.  
The fact that P30 was increased with lower MMSE scores suggests an inverse association between 
prefrontal-to-parietal connectivity and cognitive decline: as disease severity advances, left DLPFC 
connectivity becomes stronger. This finding is substantiated by fMRI studies that indicated hyper-
connectivity of prefrontal areas in AD (Agosta et al., 2012; Zhang et al., 2016). Investigating 
functional connectivity between core regions underlying episodic memory performance, Zhang and 
colleagues (Zhang et al., 2016) found that the strength of connections between left frontal and right 
parietal areas increased as a function of disease severity.  
It is also interesting to note that the AD-associated alterations of effective connectivity of left 
DLPFC seem to be selective. P50 and P70, which were localized in other areas of the prefrontal 
cortex, showed no significant relationship with AD severity. It has been shown that the left DLPFC 
is part of several networks such as frontoparietal and default-mode networks. It has also been shown 
that stimulation of DLPFC can activate both of these networks (Opitz et al., 2016). The selective 
association of P30, with no other effects on the TEP responses within the 100 ms after TMS, may 
indicate that only specific networks are relevant for the cognitive and memory decline associated 
with different illness stages. The results of this study do not allow to disentangle which is the 
network primarily involved in the worsening of AD symptoms but they pave the way for further 
studies. Cutting-edge TMS–EEG technical improvements will permit to tailor more precisely and 
individually the stimulation site based on patients’ brain scans, thus identifying the target network.  
Previous results from TMS–EEG co-registration studies targeting the motor cortex in AD patients, 
though partially contrasting, have highlighted a consistent alteration of P30 response. Ferreri and 
colleagues (Ferreri et al., 2016) reported local hyperexcitability indexed by an increase in P30 
amplitude in mild AD. The authors speculated that higher local activity may reflect plastic 
reorganization of the sensorimotor system and might serve as a compensatory mechanism able to 
preserve motor functioning in this sample of patients (Ferreri et al., 2016). Conversely, a previous 
study showed that P30 amplitude was reduced in early stages of AD, corresponding to a widespread 
disruption of the sensorimotor system (Julkunen et al., 2008). Moreover, P30 was related with 
disease severity in mild-stage AD, with decreasing amplitudes for more impaired cognitive 
functioning (Julkunen et al., 2011).  
It has been suggested that gamma-aminobutyric acid (GABAA) postsynaptic receptors are involved 
in the generation and modulation of P30 (Ferreri et al., 2011). Three classes of receptors (GABAA, 
GABAB and GABAC/ GABAA-ρ) mediate the inhibitory actions of GABA (the major inhibitory 
neurotransmitter in the brain); GABAA regulates most of the fast inhibitory neurotransmission 
(Rissman and Mobley, 2012). Therefore, P30 might be considered as a signature of corticocortical 
GABAA inhibitory circuits and its increased amplitude might indicate that the moderate stage of 
AD severity is associated with a boost of inhibitory mechanisms. However, these results were 
obtained by stimulating the motor cortex, which does not necessarily parallel changes in the 
prefrontal cortex. 
We also explored how prefrontal connectivity alterations at rest reflect memory impairment. P30 
was found to predict memory (i.e., FNAT) performance: as P30 amplitude increases, memory 
impairment worsens. This finding may allow us to understand the functional implication of 
prefrontal-to-parietal hyperconnectivity, providing suggestions to further disentangle whether such 
increased recruitment reflects a compensatory or a pathogenic mechanism. The hypothesis of 
“successful compensation” (Scheller et al., 2014) does not seem to be supported by our results, 
because enhanced prefrontal connectivity is correlated with more severe memory impairment 
(although a partial compensation may be present). The present finding resonates with the idea put 
forward by Pievani and colleagues (Pievani et al., 2014, 2011), who suggested that connectivity 
enhancement might represent a maladaptive pathogenic mechanism, which, in turn, might reflect 
damaged excitatory–inhibitory balance between anterior and posterior brain regions. Otherwise, our 
results might be interpreted in the framework of a failed “attempted compensation” (Scheller et al., 
2014), according to which hyperconnectivity is the signature of the ineffective attempt to recruit 
additional regions to compensate for pathology (Pievani et al., 2014). This does not mean that there 
cannot be some underlying compensation going on: perhaps, the fast posterior connectivity decline 
may be compensated by the prefrontal connectivity increase which may not be sufficient to avoid 
the functional deficit.  
In this sample of AD patients, P30 amplitude was found to have a good predictive performance 
(AUC=0.78) in discriminating between mild and moderate AD, thus endorsing this measure as a 
potential connectivity marker of disease severity (sensitivity: 92%; specificity: 62%). TMS–EEG 
has been already successfully applied to develop connectivity-based biomarkers for prediction, 
diagnosis or prognosis of various neuropsychiatric conditions (Farzan et al., 2016) such as 
consciousness disorders (Casali et al., 2013; Ragazzoni et al., 2013) or epilepsy (Kimiskidis, 2016). 
P30 may thus potentially represent a future connectivity marker able to predict disease severity in 
overt AD with important implications in AD research as it could help to: 1) monitor the efficacy of 
clinical interventions (potentially also during TMS therapy) and their ability to modify the course of 
the disease, 2) identify patients at risk for more severe clinical outcome, and 3) improve 
understanding of AD pathophysiology (Cummings and Zhong, 2014; Hampel et al., 2010; 
Hendrickson et al., 2015; Neugroschl and Davis, 2002).  
 
4.1 Limitations and future directions  
Although these results appear promising, a few issues need to be considered. First, this study 
has been performed in a relatively small sample so the results need to be confirmed in larger 
cohorts. This is particularly important in order to confirm that TMS–EEG can provide a 
reliable diagnostic biomarker of AD severity. Second, longitudinal studies assessing long-term 
changes are needed to take a step towards the development and validation of P30 as 
biomarker of AD progression. Indeed, considering the cross-sectional design of the present 
study, conclusions must be drawn with caution. Third, further studies could attempt to adopt 
advanced methodological improvements in the acquisition and analysis of TMS–EEG data to 
obtain more accurate network-based connectivity estimation and thus improve classification 
accuracy.  
 
5. Conclusions 
Despite the growing body of evidence regarding connectivity alterations in AD, only a few studies 
have investigated how these alterations are associated with clinical symptoms in AD across 
different severity stages.  The present study demonstrated that TMS–EEG can reveal resting-state 
connectivity alterations related to overt AD which, in turn, are able to predict disease severity. 
Specifically, we have shown that increased disease severity is associated with a boost in long-
distance interhemispheric frontoparietal signal propagation and connectivity. Our findings allowed 
also to disentangle the functional implication of prefrontal hyperconnectivity, showing that the 
additional recruitment possibly represents a maladaptive pathogenic mechanism rather than a true 
compensatory phenomenon, which might indicate a progressive impairment in the excitatory–
inhibitory balance between anterior and posterior brain regions.  
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Table 1. Demographic, clinical and neuropsychological results. 
Demographic, clinical and neuropsychological results of the final sample of patients reported as 
mean (± standard deviation). Results of the t-test or Chi-square test (p-value) between mild and 
moderate AD patients are reported. Abbreviations: BADL, Basic Activities of Daily Living; IADL, 
Instrumental Activities of Daily Living; MMSE, Mini Mental State Examination; CDR, Clinical 
Dementia Rating scale; FNAT, face name association task; ROCF, Rey Osterrieth Complex 
Figure; RBM, Rivermead Behavioral Memory test; RAVL, Ray Auditory Verbal Learning test; 
TMT, Trail Making test; BADA, Battery of Analysis of Aphasic Deficits.  
 
Figure 1. TMS-EEG results. 
A) Butterfly plot of the grand-averaged TMS-evoked potentials from all the electrodes showing the 
main components elicited by left dorsolateral prefrontal cortex (DLPFC) stimulation. The signal 
from the target site of stimulation (electrode F3) is depicted by the red line; B) Topographic 
distribution and C) sLORETA source localization for each TEP component before 100 ms. 
 
Figure 2. Relationship between P30 amplitude and MMSE score. 
A) Scatter plot showing the significant negative correlation between P30 amplitude and Mini 
Mental State Examination (MMSE) score; B) Receiver operating characteristics curve (ROC) of 
P30 amplitude discriminating between mild and moderate AD patients. The diagonal line indicates 
the null hypothesis of AUC=0.5.  
 
Figure 3. Relationship between P30 amplitude and FNAT accuracy score. 
Scatter plot showing the significant negative correlation between P30 amplitude and face–name 
association memory task (FNAT) accuracy. 
 
 Table 1. 
Demographic and clinical features    
 Total sample (26) Mild AD (13) Moderate AD (13) p-value 
Age (years) 76.5 (4.7) 75.8 (5.2) 77.2 (3.8) 0.44 
Gender (males/females) 3/23 2/11 1/12 0.54 
Education (years) 7.7 (4.1) 9.1 (5.0) 6.2 (2.1) 0.08 
BADL (unspared functions) 0.3 (0.5) 0.3 (0.5) 0.2 (0.6) 0.72 
IADL (unspared functions) 3.3 (1.8) 3.2 (1.7) 3.5 (1.7) 0.59 
MMSE  20.8 (2.5) 22.8 (1.9) 18.8 (0.9) < 0.001 
CDR 1.3 (0.5) 0.9 (0.2) 1.7 (0.5) < 0.001 
Experimental computerized task to assess episodic associative memory 
FNAT, correct responses (%) 28.3 (6.4) 31.6 (5.7) 25.0 (5.2) 0.02 
Neuropsychological assessment    
Memory     
ROCF recall 0.2 (0.6) 0.2 (0.8) 0.2 (0.4) 0.77 
RBM story recall, immediate 1.0 (1.0) 1.4 (1.1) 0.6 (0.6) 0.08 
RBM story recall, delayed 0.2 (0.5) 0.4 (0.6) 0.1 (0.3) 0.30 
RAVL recall, immediate 18.4 (6.7) 22.7 (6.5) 14.1 (3.2) 0.002 
RAVL recall, delayed 1.3 (1.5) 2.0 (1.6) 0.6 (1.0) 0.04 
Praxia     
ROCF copy 16.3 (10.1) 16.4 (9.0) 16.2 (11.0) 0.95 
Attentive functions     
TMT A 133.0 (90.6) 91.2 (56.1) 174.8 (98.8) 0.02 
TMT B 448.3 (117.6) 386.6 (117.0) 510.0 (79.6) 0.006 
Language     
BADA, oral object naming  66.5 (21.6) 75.6 (21.5) 57.4 (20.3) 0.04 
BADA, oral action naming 61.3 (21.6) 72.7 (15.1) 49.9 (21.1) 0.006 
BADA, sentence comprehension 82.9 (10.6) 87.5 (9.7) 78.4 (9.4) 0.03 
 
